GlassScriptPhysician profile
Moheb Boktor
NPI 1811187354
$1,911.84
in general payments reported to CMS, 2019-2025
16 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $18.17 · 2021: $108 · 2022: $199 · 2023: $322 · 2024: $74.21 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.38 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.90 | 2019-2025 | Linzess |
| Janssen Biotech, INC. | $434.73 | 2022-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $305.93 | 2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $84.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.03 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.33 | 2019 | |
| Boston Scientific Corporation | $39.93 | 2019 | |
| Pfizer INC. | $31.09 | 2019-2020 | |
| Lilly USA, LLC | $26.48 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $22.40 | 2022 | |
| Medtronic, INC. | $21.62 | 2024 | Gi Genius |
| Dynavax Technologies Corporation | $19.95 | 2025 | Heplisav-B |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moheb Boktor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.